How your generosity has helped
Discovering a cure for glioblastoma continues to be a long journey, but thanks to your generosity we have funding projects that are focused on improve the quality and duration of those diagnosed and, one day, will find a cure for this terrible disease.
To ensure Dunn With Cancer is making the largest impact, 100% of funds donated to the Dunn With Cancer Research Fund goes towards glioblastoma research.
Phedias Diamandis – University Health Network/Princess Margaret Cancer Centre
“Development of deep learning approaches for deciphering and targeting intra-tumoural heterogeneity in Glioblastoma”
What this project is focused on
Glioblastoma is the most common and aggressive form of brain cancer with an expected survival of only ~12-15 months from diagnosis despite spirited surgical/medical therapy. This poor outlook has remained fairly unchanged over the past half century despite many breakthroughs in our understanding of glioblastoma biology.
One recent explanation for these previous failures is that while we often think of a patient’s tumour being a homogenous mass of identical cancer cells, there are in fact a number of tumour sub-clones within each glioblastoma that respond differently to therapy. This means that existing treatments may not equally target all tumour cells and allow resistant subclones to survive and drive disease recurrence/progression.
Approaches that can help the routine characterization and personalized management of these tumour subpopulations, could provide an effective means of better controlling glioblastoma. To address this, Dr. Diamandis’ Lab plans to harness expertise in artificial intelligence to explore if this technology can help automate detection of biologically distinct tumour subregions.
Routine detection and characterization of tumour subclones, within each individual patients’ tumour, could help propose personalized and effective drug combinations that together target a larger fraction of the overall tumour biology. This could ultimately provide more durable responses for patients.
David Fortin – Universite de Sherbrooke
“Radioisotope Embedded in GlioTrap for Glioblastoma Treatment”
What this project is focused on
One of the major difficulties in treating Glioblastoma is the impossibility to remove all the tumour cells with surgery. Indeed, some tumour cells break away from the tumour nodule and invade the surrounding brain provoking recurrence.
Hence, to eliminate these tumour cells, we have developed a device that can be implanted in the tumour cavity following tumour removal. In a global project coined GlioTrap, we have designed a biocompatible gel to deliver molecules that can attract tumour cells. This gel also releases slowly antitumour drugs.
This has already been tested in an animal model. To increase the anti-tumoural effect of the device, we also want to embed a short-range radioisotope into the gel. This proposal specifically regards this aspect.
When completed, GlioTrap will: 1- chemoattract the migrating tumour cells to regroup them close to the tumour cavity; 2- gradually release high-doses of antitumoral drug locally; 3- deliver a high dose of radiation in a short range to the tumour cells. The regional effect of GlioTrap will allow to have an optimal tumour control at relapse as well as a minimal side effects.